Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
1.030
+0.120 (13.19%)
At close: Mar 9, 2026, 4:00 PM EDT
1.090
+0.060 (5.83%)
After-hours: Mar 9, 2026, 5:47 PM EDT
Nexentis Technologies Revenue
Nexentis Technologies had revenue of $2.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $209.00K, up 19.85% year-over-year. In the year 2024, Nexentis Technologies had annual revenue of $210.00K, down -20.15%.
Revenue (ttm)
$209.00K
Revenue Growth
+19.85%
P/S Ratio
12.23
Revenue / Employee
$41,800
Employees
5
Market Cap
2.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.00K | -53.00K | -20.15% |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Beauty Health Company | 301.92M |
| European Wax Center | 206.63M |
| Acme United | 196.54M |
| Grove Collaborative Holdings | 173.72M |
| Solesence | 62.15M |
| Tantech Holdings | 41.98M |
| United-Guardian | 10.06M |
| Raytech Holding | 9.39M |
NXTS News
- 18 days ago - N2OFF, Inc. Provides Early Warning Disclosure - TheNewswire
- 5 weeks ago - In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions - GlobeNewsWire
- 6 weeks ago - N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform - GlobeNewsWire
- 7 weeks ago - N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions - GlobeNewsWire
- 2 months ago - N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake - GlobeNewsWire
- 2 months ago - N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy - GlobeNewsWire
- 3 months ago - N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination - GlobeNewsWire
- 4 months ago - N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers - GlobeNewsWire